453 reports of this reaction
2.7% of all LAMIVUDINE AND ZIDOVUDINE reports
#7 most reported adverse reaction
ANAEMIA is the #7 most commonly reported adverse reaction for LAMIVUDINE AND ZIDOVUDINE, manufactured by ViiV Healthcare Company. There are 453 FDA adverse event reports linking LAMIVUDINE AND ZIDOVUDINE to ANAEMIA. This represents approximately 2.7% of all 16,773 adverse event reports for this drug.
Patients taking LAMIVUDINE AND ZIDOVUDINE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for LAMIVUDINE AND ZIDOVUDINE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for LAMIVUDINE AND ZIDOVUDINE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 453 FDA reports for LAMIVUDINE AND ZIDOVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.7% of all adverse event reports for LAMIVUDINE AND ZIDOVUDINE, making it a notable side effect.
If you experience anaemia while taking LAMIVUDINE AND ZIDOVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.